Prostate Cancer

Researchers at Weill Cornell Medicine have developed tiny silica nanoparticles that destroyed aggressive prostate cancer tumors in mice while boosting the immune system. The treatment led to complete remissions when combined with immunotherapy.

2025년 11월 10일 AI에 의해 보고됨

An international team has discovered that prostate cancer cells depend on two enzymes, PDIA1 and PDIA5, for survival and resistance to therapy. Blocking these enzymes destabilizes the androgen receptor, leading to cancer cell death and improved drug efficacy. The findings, published in PNAS, suggest new ways to combat advanced prostate cancer.